Equities Analysts Offer Predictions for Cencora Q2 Earnings

Cencora, Inc. (NYSE:COR) – Equities research analysts at Leerink Partnrs increased their Q2 2025 earnings per share estimates for shares of Cencora in a research note issued on Thursday, January 2nd. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $4.23 per share for the quarter, up from their previous forecast of $4.12. The consensus estimate for Cencora’s current full-year earnings is $14.93 per share. Leerink Partnrs also issued estimates for Cencora’s Q3 2025 earnings at $3.87 EPS, Q4 2025 earnings at $3.84 EPS, FY2025 earnings at $15.39 EPS, FY2026 earnings at $17.11 EPS and FY2028 earnings at $20.75 EPS.

COR has been the topic of several other reports. Wells Fargo & Company dropped their price objective on Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a report on Friday, December 13th. Mizuho assumed coverage on Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price for the company. UBS Group lifted their target price on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Finally, Evercore ISI lifted their target price on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.60.

Cencora Price Performance

COR stock opened at $229.20 on Monday. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. Cencora has a 52-week low of $207.63 and a 52-week high of $253.27. The stock’s 50 day moving average is $237.44 and its two-hundred day moving average is $233.60. The company has a market capitalization of $44.30 billion, a PE ratio of 30.52, a P/E/G ratio of 1.54 and a beta of 0.45.

Institutional Trading of Cencora

Several hedge funds have recently added to or reduced their stakes in the business. Lake Street Advisors Group LLC raised its stake in Cencora by 1.3% during the 3rd quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company’s stock valued at $769,000 after acquiring an additional 43 shares in the last quarter. Venturi Wealth Management LLC raised its stake in Cencora by 1.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company’s stock valued at $1,001,000 after acquiring an additional 46 shares in the last quarter. Prime Capital Investment Advisors LLC raised its stake in Cencora by 1.2% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company’s stock valued at $848,000 after acquiring an additional 46 shares in the last quarter. J.W. Cole Advisors Inc. raised its stake in Cencora by 1.3% during the 3rd quarter. J.W. Cole Advisors Inc. now owns 3,669 shares of the company’s stock valued at $826,000 after acquiring an additional 48 shares in the last quarter. Finally, Impact Partnership Wealth LLC raised its stake in shares of Cencora by 2.6% in the 3rd quarter. Impact Partnership Wealth LLC now owns 2,042 shares of the company’s stock worth $460,000 after buying an additional 51 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In related news, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. The trade was a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 50,000 shares of Cencora stock in a transaction on Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the sale, the chairman now directly owns 326,557 shares in the company, valued at $79,670,111.29. The trade was a 13.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 94,696 shares of company stock worth $22,862,734 in the last 90 days. 15.80% of the stock is currently owned by company insiders.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.96%. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s payout ratio is currently 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.